April2018

SafeHarborStatement

CertainmattersdiscussedinthispresentationandoralstatementsmadefromtimetotimebyrepresentativesoftheCompanymayconstituteforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995andtheFederalsecuritieslaws. AlthoughtheCompanybelievesthattheexpectationsreflectedinsuchforward-lookingstatementsarebaseduponreasonableassumptions,itcangivenoassurancethatitsexpectationswillbeachieved.

Forward-lookinginformationissubjecttocertainrisks,trendsanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromthoseprojected. ManyofthesefactorsarebeyondtheCompany’sabilitytocontrolorpredict. ImportantfactorsthatmaycauseactualresultstodiffermateriallyandthatcouldimpacttheCompanyandthestatementscontainedinthispresentationcanbefoundintheCompany’sfilingswiththeSecuritiesandExchangeCommissionincludingourmostrecentreportsonForm10-KandForm10-Q.CopiesofthesefilingsareavailableonlinefromtheSEC. Forforward-lookingstatementsinthispresentation,theCompanyclaimstheprotectionofthesafeharborforforward-lookingstatementscontainedinthePrivateSecuritiesLitigationReformActof1995. TheCompanyassumesnoobligationtoupdateorsupplementanyforward-lookingstatementsasaresultofnewinformation,futureevents,orotherwise.

InvestmentHighlights

3

“Core”and“OEM”operatingsegments:establishedcommercialbusinesseswithstrongprofitabilityandcashflow

AdvancedEnergyoperatingsegment:BovieMedical’s‘growthengine’

J-Plasma®:transformationaltechnology,supportedbystrongandgrowingIPportfolio

AdvancedEnergysegmentgrowthfueledbycommercializationofJ-Plasma®technologyinthecosmeticsurgerymarket

Experiencedmanagementteam;enhancedwithrecenthires

Solidbalancesheetconditionsupportedbyimprovinggrowthandprofitabilityprofile

Long-termAdvancedEnergygrowthprofileenhancedbyclinical,regulatory&marketinginitiatives

ExperiencedManagementTeamMgmt.TeamMember JoinedBovie RepresentativePreviousExperience

CharlieGoodwinChiefExecutiveOfficer December2017

JayEwersChiefFinancialOfficer June2014

ToddHornsbyVicePresident&General

ManagerofAdvancedEnergyAugust2014

4

RobSaronPresidentandDirector January1978

MosheCitronowiczSeniorVicePresident October1993

YearsofRelevantExperience

25

35

18

36

31 KCRTechnologies SequentialInformationSystems

Dr.TopazKirlewDirectorofRegulatoryAffairs March2018 30

Experiencedmanagementteam;enhancedwithrecenthires

ScottSandersDirectorofClinicalEducation

&MarketDevelopmentMarch2018 37

5

CompanySnapshot

Core

Energy-based medical device company specializing in developing, manufacturingand marketing a range of electrosurgical products and technologies, as well asrelated medical products used in doctor’s offices, surgery centers and hospitalsworldwide.

Founded: 1978

Locations: • Clearwater,FL• Sofia,BulgariaFull-Time Employees: 211**

CommercialProfile: >300 products soldin>150countries

LTMSales(12/31/17): $38.9M

OperatingSegments:• Core• OEM• AdvancedEnergy

Yearof IPO: 1982

NYSEMKT: BVX

MarketCap: ~$104M*

Avg.DailyVol(LTM): ~104,000

*

*Shareprice:$3.15asofmarketcloseon3/15/2018;Sharesoutstanding:33.0Masof3/9/2018**Asof12/31/2017LTM=“LastTwelveMonths”

99.3% 95.6%90.4%

80.4%

FY'14 FY'15 FY'16 FY'17

OEMCore

OperatingSegments:“Core”&“OEM”• Legacybusinessesfocusedonthedesignand

manufactureofelectrosurgicaltechnologiesandaccessories:

- “Core”productsmarketedandsoldthroughdistributorsworldwideto>6,000hospitals

- “OEM”productsmanufacturedinresponsetoinbounddemandfromlargemedicaldevicecompanies

Core/OEMFinancialProfile:• Modestannualrevenuegrowthovermulti-yr.period

- Core/OEM’14-’17CAGRof~4%;volatilityinannualgrowthratesdrivenbyfluctuationsinOEMdemand

- Core/OEMshareoftotalcompanyrevenuedecreasingduetostrongrevenuegrowthfromAdvancedEnergysegmentinrecentyears

• Strongprofitabilityandcashflowprofile

6

Establishedcommercialbusinesseswithstrongprofitabilityandcashflow

$27.5M $28.2M$33.1M $31.2M

FY'14 FY'15 FY'16 FY'17

Core/OEM:AnnualRevenueOEMCore

Core/OEM:PercentofAnnualCompanyRevenue

$0.2M$1.3M

$3.5M

$7.6M

$10.9M

FY'14 FY'15 FY'16 FY'17 FY'18GuidanceMidPt.

• Advancedelectrosurgicalandplasmatechnology(generatorsandhandpieces)

• PrimarydriverofBovie’slong-termrevenuegrowth

• CommercializedproductsmarketedintheU.S.viahybridsellingorganizationandinternationallyviadistributors

- U.S.hybriddistributionnetworkasof12/31/17:- 14directreps- 3regionalmanagers- 14independentreps

OperatingSegment:“AdvancedEnergy”

7

Adv.Energy:20%

PercentofFY’17Revenue

BovieMedical’s‘growthengine’

AdvancedEnergy:AnnualRevenue

AdvancedEnergy:J-Plasma®Technology

• Revolutionarytechnologyionizesheliumtocreatestreamofplasmaforcutting,coagulatingandablatingsofttissue

• Superiorprecision,withlimitedthermalspread

- Stable,thin,focusedstreamofionizedheliumgas- Widerangeofcontrol

• Allowsphysicianstosafelyperformproceduresonorarounddelicatestructures

8

UniqueRetractableBlade

Transformationaltechnology

J-PlasmaTechnology:LimitedThermalDamagevs.Energy-basedSurgicalTools*

• Prospectivestudycomparedlevelsofunintendedthermaldamagetoperitonealtissue(membraneliningtheabdominalcavity)amongotherenergy-basedsurgicaltoolsvs.J-Plasma

• Redareasrepresentthedepthofthermalorenergydamageeachtoolleftbelowthetissuesurface;blueareasrepresentunaffectedtissue

• J-Plasmademonstratedfarlowestamountofcollateralthermalinjurytohealthytissuesurroundingtheoperativesite

*Reference:PedrosoJ,GutierrezM,VolkerW.J-Plasma,monopolarpencil,argonbeamandCO2laserelectrosurgery:comparativeevaluationofthermalspreadinaporcinetissuemodel(whitepaper).BovieMedicalCorporation.June2014 9

J-PlasmaTechnology:DemonstrationVideo

10

VideoURL:http://www.boviemedical.com/downloads/J-Plasma_Demonstration_Video.mp4

Ifyouarehavingtroubleviewingvideo,chooseotheroption.

TodownloadaWindowsMediaVideoversionclickhere.https://cloud.boviemedical.com/index.php/s/4E5Uwb0hcscxNPp

FlashorQuickTimePlayerrequiredtoview.

ToviewvideofromYouTubeclickhere.https://youtu.be/UsnKHLvrmnY

J-PlasmaTechnology:ClinicianFeedback

11

“J-PlasmadeliversthemostprecisionIhaveeverseeninanenergy-baseddevice.Thisallowsthephysiciantotreatsmallandlargeareaswithease.TheamountofenergycanbetailoredtogetoutcomesIhavenotyetseenwithanycompetitivelaserdevice.”

-JasonEmer,M.D.,FAAD,FAACSDermatologicSurgeon

“J-PlasmaisatrulyinnovativetechnologythatwillbeinvaluabletoFacialandPlasticSurgeonsandDermatologists.Thethermalcharacteristicsofthisenergy-baseddeviceareunlikeanydevicescurrentlyavailable.”

-RichardGentile,M.D.,MBAPlasticSurgeon

“Thereisanincredibleamountofcontrolintermsofdepth-of-penetration;becauseit’snotdeliveringaburningenergy”“It’sachancetobeartistic,becauseyouareusingadevicemorelikeapaintbrushthananatombomb.”

-JosephB.DeLozier III,MD,FACSPlasticSurgeon

“J-Plasmaisfast,easytouseandIamhappywiththeresults.ThisisoneofthefewdevicesIhavepurchasedthatwon'tspendanytimeinthecloset.”

-DianeDuncan,M.D.PlasticSurgeon

“J-Plasmaisaninnovativeenergy-baseddevicewithanimpactontissueunlikeanydevicecurrentlyavailable.J-PlasmawillcreateafundamentalshiftinthewayproceduresareperformedbyallPlasticSurgeons,CosmeticSurgeonsandDermatologists.”

-JackZamora,M.D.OculoplasticSurgeon

AdvancedEnergy:CommercialFocus

U.S.commercialfocus" cosmeticsurgerymarket:

• U.S.cosmeticsurgerymarketcomprisedof~15,000*plasticsurgeons,cosmeticsurgeons&dermatologists

• FavorableU.S.marketcharacteristics:Proceduresperformedinoutpatientfacilitiesandpaidforoutofpocket

• StronginitialU.S.commercialtraction:hybridsalesforcefocusedonearlyadopters

- Initialproceduralareafocus:subdermalcoagulationfollowingliposuction(~200Kannualliposuctionproceduresinplasticsurgeryalone**)

Internationalcommercialfocus" soldtodistributors,whomarketandsellintothehospitalsurgicalsuite

12

AdvancedEnergysegmentgrowthfueledbycommercializationofJ-Plasmatechnologyinthecosmeticsurgerymarket

*American Society of Plastic Surgeons (ASPS) database 2016**American Society for Aesthetic Plastic Surgery (ASAPS) database 2016

DevelopingExpertiseintheCosmeticSurgeryMarket

1. Enhancingphysicianandpracticesupportforcosmeticsurgerycustomers

- Currentfocus: launchofnewchannel-dedicatedbrand-- Recentmilestone: InitiatedRenuvion™brandlaunchonMarch29th

2. ExpandingclinicalsupportforJ-Plasmaincosmeticsurgeryprocedures

- Currentfocus: IDEprospective,multicenter,singlearmclinicalstudyevaluatingthe_____________useofJ-Plasma®fordermalskinresurfacing

- Upcomingmilestone: expecttocompletestudyenrollmentbyendofQ2’18

3. Pursuingnew,specificclinicalindicationsinthecosmeticsurgerymarket:

- Currentfocus: FDA510(k)specificindicationforuseindermalskinresurfacingprocedures- Upcomingmilestone: expecttosubmitforregulatoryindicationbyendofFY‘18

13

Long-termAdvancedEnergygrowthprofileenhancedbyclinical,regulatory&marketinginitiativesincosmeticsurgery

Focusedonbuildingsupporttofacilitatebroad-basedadoptionby:

IntroducingRenuvion™CosmeticTechnology

• Anewbranddedicatedtothecosmeticsurgerymarket:

- - BovieMedical’sJ-PlasmatechnologyisnowbeingmarketedandsoldinthecosmeticsurgerymarketundertheRenuvionbrandname

• Createdforphysiciansinthecosmeticsurgerymarket

- Physicianfeedbackfromearly-adoptersofJ-Plasmatechnologyinstrumentalincreatingabrand/campaignthatwillresonatewithcosmeticsurgerycustomers

• Designedto:

- Enhancephysicianpractice-basedmarketing- LeveragetheincreasingawarenessofRenuvioninthe

cosmeticsurgerymarket

14

Renuvion:enhancingphysicianandpracticesupportforcosmeticsurgerycustomers

WhatisRenuvion?

• EstablishedIPportfolio;pendingapprovalsfocusedonAdvancedEnergysegment:

IP&NewProductDevelopment

15

GrowingIPportfolioandrecentprogressinnewproductdevelopment

PatentsIssued PatentsPending

UnitedStates 41 12

International 23 9

Total 64 21

AdvancedEnergyproductscomprise:42%ofissuedpatentsand

100%ofpendingpatents

Progress(2010– 2013):

- 4510(k)clearances- 2CEMarkapprovals- 4Productscommercialized

ProgresssinceJanuary,2014:

- 10510(k)clearances- 21CEMarkapprovals- 10Productscommercialized

• Productdevelopmenteffortsreinvigoratedin2014:

16

ManufacturingFootprint

Clearwater, FL Sofia, Bulgaria China

Size: 60,000sq.ft. 16,000sq. ft. • 70,000sq.ft.

Owned/Contracted:

Owned Owned Contracted

Capabilities:

• Assembly• Integration• FinalTesting• Packaging• SterilizationManagement

• Manufacturing• ComplexComponent

Assembly• InitialTesting

• ComponentManufacturing• Sub-Assemblies• Finished MedicalDevices

(Electrodes)

ImprovingmanufacturingcapacityandefficienciestoaccommodateanticipatedstrongdemandforJ-Plasma

17

HistoricalFinancialSummary

($in000's)2016 2017 2016 2017

Revenue $9,494 $11,348 $36,627 $38,883RevenueGrowth(Y/Y) 14.5% 19.5% 24.1% 6.2%

CostofGoodsSold 4,663 5,449 18,712 19,122

GrossProfit $4,831 $5,899 $17,915 $19,761GrossMargin 50.9% 52.0% 48.9% 50.8%

OperatingExpenses 5,875 6,987 21,707 25,026

LossfromOperations ($1,044) ($1,088) ($3,792) ($5,265)

AdjustedEBITDA ($589) ($580) ($2,249) ($3,698)

AdjustedEBITDAEx.Non-recurringitems* ($589) $944 ($2,249) ($2,174)

CashonhandasofDecember31,2017 $10,668

Q4 FY

*Fourth quarter and fiscal year 2017 periods include approximately $1.5 million of non-recurring severance andexpenses related to former members of the Company’s executive management team and related closure of thecorporate office in Purchase, New York.

18

FY’18GuidanceSummary

• FormalFinancialGuidance:

• TotalGAAPrevenueintherangeof$41.0millionto$42.5million,comparedto$38.9millioninfiscalyear2017.

• AdjustedEBITDAinarangeof$1.0millionto$1.5million,comparedtoalossof$2.2millioninfiscalyear2017.

• FY’18totalcompanyrevenueguidanceassumes:• TotalrevenuegrowthdrivenbyAdvancedEnergysegmentsales,which

areexpectedtogrow40%- 45%y/yin2018

Improvingprofitability;growthdrivenbystrongcommercialtractioninAdvancedEnergysegment

Appendix

BalanceSheet

20

(Unaudited)(Inthousands)

December31,2017

December31,2016

ASSETSCurrentassets:Cashandcashequivalents 9,949$ 14,456$Restrictedcash 719 779Tradeaccountsreceivable,netofallowanceof$204and$118 4,857 4,733Inventories,net 6,526 6,158Prepaidexpensesandothercurrentassets 496 413Totalcurrentassets 22,547 26,539

Propertyandequipment,net 6,408 6,449Brandnameandtrademark 1,510 1,510Purchasedtechnologyandlicenserights,net 179 215Goodwill 185 185Deposits 92 109Otherassets 67 103

Totalassets 30,988$ 35,110$

BalanceSheet

21

(Unaudited)(Inthousands)December31,

2017December31,

2016LIABILITIESANDSTOCKHOLDERS'EQUITYCurrentliabilities:Accountspayable 1,583$ 1,606$Accruedseveranceandrelated 1,242 —Accruedpayroll 447 419Accruedvacation 74 404Currentportionofmortgagenotepayable 239 239Accruedandotherl iabil ities 2,388 2,604Totalcurrentliabilities 5,973 5,272

Mortgagenotepayable,netofcurrentportion 2,455 2,694Notepayable 140 140Deferredrents — 14Deferredtaxl iabil ity 368 564Derivativel iabil ities 20 203Totalliabilities 8,956 8,887

STOCKHOLDERS'EQUITY

SeriesBconvertiblepreferredstock,$0.001parvalue;3,588,139authorizedandzeroissuedandoutstandingasofDecember31,2017and3,588,139authorizedand975,639issuedandoutstandingasofDecember31,2016,respectively — 1

Commonstock,$0.001parvalue;75,000,000sharesauthorized;33,021,170issuedand32,878,091outstandingasofDecember31,2017and40,000,000sharesauthorized;31,002,832issuedand30,859,753outstandingasofDecember31,2016,respectively 33 31Additionalpaid-incapital 50,495 49,625Accumulateddeficit (28,496) (23,434)Totalstockholders'equity 22,032 26,223Totalliabilitiesandstockholders'equity 30,988$ 35,110$

IncomeStatement

22

(Unaudited)(Inthousands,exceptpersharedata)

2017 2016 2017 2016Sales 11,348$ 9,494$ 38,883$ 36,627$Costofsales 5,449 4,664 19,122 18,712Grossprofit 5,899 4,830 19,761 17,915Othercostsandexpenses:Researchanddevelopment 440 676 2,455 2,618Professionalservices 480 441 1,771 1,486Salariesandrelatedcosts 1,123 2,546 7,906 9,038Selling,generalandadministrative 3,420 2,211 11,370 8,565Severanceandrelatedexpense 1,524 — 1,524 —Totalothercostsandexpenses 6,987 5,874 25,026 21,707Lossfromoperations (1,088) (1,044) (5,265) (3,792)Interestexpense,net (33) (35) (136) (158)Changeinfairvalueofderivativel iabil ities 126 620 183 64Totalotherincome(loss),net 93 585 47 (94)Lossbeforeincometaxes (995) (459) (5,218) (3,886)Incometax(benefit)expense (171) 64 (156) 64Netloss (824)$ (523)$ (5,062)$ (3,950)$

LosspershareBasic (0.03)$ (0.02)$ (0.16)$ (0.14)$Diluted (0.03)$ (0.02)$ (0.17)$ (0.15)$

Weightedaveragenumberofsharesoutstanding-basic 32,864 28,574 31,420 27,433Weightedaveragenumberofsharesoutstanding-dilutive 32,864 28,618 31,427 27,449

ThreeMonthsEndedDecember31,

TwelveMonthsEndedDecember31,

ReconciliationBetweenGAAPandNon-GAAP

23

(Unaudited)(Inthousands)

*Fourth quarter and fiscal year 2017 periods include approximately $1.5 million of non-recurringseverance and expenses related to former members of the Company’s executive management teamand related closure of the corporate office in Purchase, New York.

2017 2016 2017 2016NetlossGAAPBasis (824)$ (523)$ (5,062)$ (3,950)$Interestexpense,net 33 35 136 158Incometax(benefit)expense (171) 64 (156) 64Depreciationandamortization 169 178 696 734Stockbasedcompensation 339 277 871 809Changeinfairvalueofderivativeliabilities (126) (620) (183) (64)AdjustedEBITDA (580) (589) (3,698) (2,249)Severanceandrelatedexpense 1,524 — 1,524 —AdjustedEBITDA,excludingnon-recurringitems* 944 (589) (2,174) (2,249)

ThreeMonthsEndedDecember31,

TwelveMonthsEndedDecember31,